8-KEarnings & ResultsExhibits & Filings

DEXCOM INC 8-K Report, Financial Results (May 2, 2018)

Filed May 2, 2018For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K on May 2, 2018, to announce its financial results for the first quarter ended March 31, 2018. The filing primarily references a press release (Exhibit 99.01) that details the company's performance and other relevant information. Investors should note that this information is furnished and not deemed filed under Section 18 of the Exchange Act, meaning it's not subject to the same liability provisions.

Key Highlights

  • 1DexCom announced its first quarter 2018 financial results on May 2, 2018, via an 8-K filing.
  • 2The core of the announcement is contained within an attached press release (Exhibit 99.01).
  • 3The press release provides details on the company's financial performance for the quarter ending March 31, 2018.
  • 4Information provided is furnished under Item 2.02 and is not considered 'filed' for regulatory liability purposes under Section 18 of the Exchange Act.
  • 5This filing serves as the primary disclosure vehicle for the Q1 2018 results and associated commentary.
  • 6Investors should refer to the referenced press release for specific financial metrics and operational updates.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce DexCom's financial results for the first quarter ended March 31, 2018, and to provide other relevant company information through an attached press release.

The detailed financial results and other pertinent information are located in the press release furnished as Exhibit 99.01 to this 8-K filing.

No, the information provided in this Item 2.02 filing, including the press release, is furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. This means it is not subject to the liabilities associated with that section.

No, the information contained in this filing and its exhibit is not automatically incorporated by reference into any other DexCom filings under the Securities Act or the Exchange Act.